


Author Index

VOLUME 23, 2003

Note: Numbers preceded by S indicate pages in Volume 23, Supplement 1.

- Alison, Malcolm R., 325
Alter, Miriam J., 39
- Bartholomeusz, Angeline, 5
Bernal, William, 227
Blei, Andres T., 259
Brady, Lynda, 195
Broderick, Annemarie L., 59
Burger, Susanne, 115
Butterworth, Roger F., 251
- Cahill, Michael E., 259
Cheng, Vincent C.C., 239
Chung, Chuhan, 259
Craxi, Antonio, S35
Crosby, Heather A., 373
- Dabeva, Mariana D., 349
Desmet, Valmeer J., 385
Dieterich, Douglas T., 107, 173
Dixit, Narendra M., S13
- Fattovich, Giovanna, 47
Fontona, Robert J., 89
- Goldar-Najafi, Atoussa, 101
Gonzalez, Stevan A., 149
Grisham, Joe W., 301, 303
Grompe, Markus, 363
- Hadziyannis, Stephanos J., 81
Harris, M., 167
- Hart, John, 195, 295
Heathcote, Jenny, 69
Herrmann, Eva, S23
Hubscher, Stefan G., 373
- Jalan, Rajiv, 271
Jonas, Maureen M., 59
- Keeffe, Emmet B., S1
Kelly, Deirdre A., 373
Khettry, Urmila, 101
Kontorinis, Nicholas, 173
- Lau, George K.K., 239
Layden, Thomas J., S29
Layden-Almer, Jennifer E., S29
Lee, William M., 217
Libbrecht, Louis, 385
Licata, Anna, S35
Lo, Chung-Mau, 239
Locarnini, Stephen, 5
Lok, Anna, 1
- Mcmilland, Janine, 5
Montessori, Valentina, 167
Montaner, Julio S.G., 167
- Nijjar, Sarbjit, 373
- Papatheodoridis, George V., 81
Pawlotsky, Jean-Michel, S3
Pedder, Simon C. J., S19
Perelson, Alan S., S13
- Poles, Michael A., 115
Powers, Kimberly A., S13
- Rehermann, Barbara, 21
Riordan, Stephen M., 203
Roskams, Tania, 385
- Sahoo, Sunati, 295
Sen, Sambit, 283
Shafritz, David A., 349
Sherman, Kenneth E., S47
Stapleton, Jack T., 137
Strain, Alistair J., 373
Strick-Marchand, Hélène, 313
Sulkowski, Mark S., 183
- Talal, Andrew H., 149, S13
Taniguchi, Hideki, 337
Thio, Chloe L., 125
Thorgeirsson, Snorri S., 301, 303
- Vaquero, Javier, 259
Vassilopoulos, Dimitrios, 81
- Weiss, Mary C., 313
Welsch, Christoph, S23
Williams, Roger, 201, 203, 283
- Yerian, Lisa M., 195
- Zeuzem, Stefan, S23
Zheng, Yun-Wen, 337



Subject Index

VOLUME 23, 2003

Note: Numbers preceded by S indicate pages in Volume 23, Supplement 1.

- Abacavir. *See* Nucleoside analogue reverse transcriptase inhibitors
- ABC membrane transporters, in hepatic stem cells, 325–335
- Acetaminophen
- acute liver failure caused by, 217–226, 227–237
 - prognostic criteria in, 203–215
 - hepatotoxicity of, 203–215, 217–226, 227–237
 - dose and, 227–237
 - package size restriction, 227–237
 - poisoning with, prevention of, 227–237
 - regulation of, in United Kingdom, 227–237
- N*-Acetylcysteine, for acute liver failure, 217–226, 271–282
- Acquired immunodeficiency syndrome (AIDS). *See* Human immunodeficiency virus (HIV)
- Adefovir dipivoxil, for chronic hepatitis B, 69–79, 81–88, 89–100, 107–114
- in HBeAg-negative disease, 81–88
 - in HBeAg-positive disease, 69–79
 - in HIV-infected (AIDS) patients, 125–136
 - in lamivudine-resistant disease, 81–88
 - with decompensated liver disease before or after transplant, 89–100
- African Americans, hepatitis C in
- peginterferons for, S47–S52
 - viral kinetics in, S29–S33
- Albuprofen, pharmacokinetics of, S23–S28
- Albumin dialysis, in acute liver failure, 283–294
- Alcohol abusers, with hepatitis C, peginterferon use in, S47–S52
- Alcoholic fatty liver disease, progenitor cell activation in, 385–396
- Ammonia
- in acute liver failure, 251–258, 259–269, 271–282
 - in hepatic encephalopathy, 251–258, 259–269
- Amprenavir, pharmacology of, 183–193
- Analgesics, regulation of, in United Kingdom, 227–237
- Anemia, ribavirin-induced, treatment of, 107–114
- Antibiotics, for systemic inflammatory response in acute liver failure, 271–282
- Antiretroviral therapy, 149–166
- hepatotoxicity of, 107–114, 149–166, 167–171, 173–181, 183–193
 - evaluation for, 107–114
- Apoptosis, hepatocyte, in acute liver failure, 203–215
- L*-Asparaginase, liver disease caused by, histopathology of, 295–299
- Asphyxiating thoracic dystrophy, hepatic manifestations of, 195–200
- Astrocytes, in acute liver failure, 251–258
- BILN 2061, for hepatitis C, 149–166
- Bioartificial liver support devices, in acute liver failure, 283–294
- Blood pressure, arterial, in acute liver failure, 259–269
- Book review, *Liver Disease in Children*, 2nd ed., 107
- Brain. *See also* Cerebral
- metabolism, in acute liver failure, 251–258
 - monitoring, in acute liver failure, 271–282
- Bromfenac, acute liver failure caused by, 217–226
- Cerebral anoxia, in acute liver failure, 259–269
- Cerebral autoregulation, in acute liver failure, 259–269
- Cerebral blood flow, in acute liver failure, 259–269, 271–282
- Cerebral edema
- in hepatic encephalopathy, 259–269, 271–282
 - in liver failure, pathogenesis of, 251–258, 259–269
- Cerebral perfusion
- in acute liver failure, 271–282
 - in hepatic encephalopathy, 259–269
- Children
- acute liver failure in, 217–226
 - hepatitis B in, 59–68
 - clinical presentation of, 59–68
 - epidemiology of, 59–68
 - natural history of, 47–58, 59–68
 - prevention of, 59–68
 - transmission of, 59–68
 - treatment of, 59–68
- Cholangiocytes, differentiation, from stem cells, 303–312, 313–324, 325–335
- Cholelithiasis, xanthogranulomatous, 101–106
- Cirrhosis
- hepatic encephalopathy in, 259–269
 - in hepatitis B
 - management of, 89–100
 - outcome with, lamivudine and, 47–58
 - and prognosis, 47–58
 - in hepatitis C, clinical manifestations of, 149–166
- Clevudine, for hepatitis B, 81–88
- Delavirdine, hepatotoxicity of, 173–181
- Dexamethasone, for systemic inflammatory response in acute liver failure, 271–282
- Didanosine. *See also* Nucleoside analogue reverse transcriptase inhibitors
- and ribavirin, interactions of, 107–114
- Drug reactions
- acute liver failure caused by, 239–250
 - idiosyncratic, acute liver failure caused by, 217–226

- Drugs. *See also specific drug*
acute liver failure caused by, 203-215, 217-226, 227-237, 239-250
liver disease caused by, histopathology of, 295-299
- Efavirenz, hepatotoxicity of, 107-114, 173-181
- Emtricitabine, for hepatitis B, 81-88
- Encephalopathy, hepatic
in acute liver failure, 271-282
cerebral edema in, 259-269
cerebral perfusion in, 259-269
monitoring of, 271-282
precipitating factors, 259-269
seizures in, 259-269
of cirrhosis, 259-269
grading of, 259-269
pathogenesis of, 251-258, 259-269
- Energy metabolism, cerebral, in acute liver failure, 251-258
- Entecavir, for hepatitis B, 89-100
in HBeAg-negative disease, 81-88
in HIV-infected (AIDS) patients, 125-136
in lamivudine-resistant disease, 81-88
- Epithelial cells. *See also Progenitor cells*
adult liver, differentiation of, 303-312
bone marrow-derived, 363-371
physiological significance of, 363-371
endogenous, as liver stem cells, 303-312
fetal liver
clonal expansion of, 349-361
hepatocyte potential of, 303-312
isolation of, 349-361
hepatic, cell lines, 349-361
- Erythropoietin (EPO), for ribavirin-induced anemia, 107-114
- Extracorporeal liver assist devices, for acute liver failure, 283-294
- Famciclovir, for hepatitis B, 89-100
and interferon, combined, 81-88
and lamivudine, combined, 69-79, 81-88
- Far East, fulminant hepatic failure in, 239-250
- Fatty liver disease
alcoholic, progenitor cell activation in, 385-396
nonalcoholic, progenitor cell activation in, 385-396
- Fever, in acute liver failure, 259-269
- Flow cytometry, of hepatic stem cells, 337-348
- Fulminant hepatic failure. *See* Liver failure, fulminant
- GB virus type C, 107-114
and hepatitis C virus, comparison of, 137-148
historical perspective on, 137-148
and human immunodeficiency virus (HIV), interaction of, 137-148
infection
in HIV-infected (AIDS) patients, 137-148
prevalence of, 137-148
and liver disease, 137-148
transmission of, 137-148
virology of, 137-148
- Glucose, in acute liver failure, 259-269
- Hepatectomy
partial, liver regeneration after, 385-396. *See also* Liver repopulation
for systemic inflammatory response in acute liver failure, 271-282
- Hepatic failure, fulminant. *See* Liver failure, fulminant
- Hepatic steatosis, with nucleoside reverse transcriptase inhibitor therapy, 167-171
- Hepatitis
seronegative, acute liver failure caused by, 239-250
viral, chronic, liver regeneration in, 385-396
- Hepatitis A
acute liver failure caused by, 217-226, 239-250
vaccine, 125-136
- Hepatitis B
acute liver failure caused by, 217-226, 239-250
acute self-limited, immune response in, 21-37
in children, 59-68
clinical presentation of, 59-68
epidemiology of, 59-68
natural history of, 47-58, 59-68
prevention of, 59-68
transmission of, 59-68
- chronic
antiretroviral therapy in, hepatotoxicity of, evaluation for, 107-114
clinical spectrum of, 47-58
"flares" of, 239-250
immune response in, 21-37
natural history of, 47-58
prognosis for, 47-58
endemic patterns of, 39-46
epidemiology of, 39-46
HBeAg-negative, 47-58
adefovir dipivoxil for, 81-88
entecavir for, 81-88
interferon for, 81-88
lamivudine for, 81-88
treatment of, 81-88
HBeAg-positive, 47-58
adefovir dipivoxil for, 69-79
interferon for, 69-79
lamivudine for, 69-79
treatment of, 69-79
HBeAg seroconversion in, 69-79
health policy toward, advances in (future directions for), 1-4
in HIV-infected (AIDS) patients
diagnosis of, 125-136
epidemiology of, 125-136
and hepatotoxicity of HIV-1 protease inhibitors, 183-193
and hepatotoxicity of non-nucleoside analog reverse transcriptase inhibitors, 173-181
natural history of, 125-136
treatment of, 125-136
immune response to, 1-4, 21-37
immunorestitution disease in, 239-250
immunotherapy for, potential for, 21-37
inactive HBsAg carrier state, 47-58

- natural history of, 1-4, 47-58
 - antiviral therapy and, 47-58
 - HIV coinfection and, 125-136
- prevention of, 1-4, 39-46, 125-136
 - in children, 59-68
- recurrence, after liver transplantation, 89-100
- research on, progress in, 1-4
- severity of, viral genotype and, 5-20
- treatment of, 1-4, 107-114. *See also* Interferon- α ;
Lamivudine
 - advances in, 81-88
 - in children, 59-68
 - combination drug therapy for, 69-79, 81-88, 125-136
 - duration of, and therapeutic effect, 69-79
 - in HBeAg-negative patients, 81-88
 - in HBeAg-positive patients, 69-79
 - immune response and, 21-37
 - outcome with, 47-58
- vaccine
 - adverse effects and side effects of, 59-68
 - in HIV-HBV coinfecting patients, 125-136
 - in infancy, 59-68
 - for neonates, 1-4, 39-46
 - strategies for, 39-46
 - therapeutic, 81-88
 - potential for, 21-37
- Hepatitis B immune globulin (HBIG), and lamivudine, combined, for HBV prophylaxis after liver transplantation, 89-100
- Hepatitis B virus (HBV)
 - genome of, 5-20, 125-136
 - genotypes of, 5-20, 125-136
 - life cycle of, 5-20
 - molecular virology of, 1-4, 5-20
 - mutants, 5-20
 - and vaccination program success, 39-46
 - mutations of
 - generation of, 5-20
 - and nucleoside resistance, 5-20, 125-136
 - selection of, 5-20
 - nucleoside resistance in, 69-79, 81-88, 89-100
 - mutations conferring, 5-20
 - perinatal transmission of, 47-58, 59-68
 - quasispecies, 5-20
 - replication of, 5-20
 - regulatory elements in, 5-20
 - transmission, geographic patterns of, 39-46
 - virion, morphology of, 5-20
 - virology of, 125-136
- Hepatitis C
 - acute, clinical features of, 149-166
 - in African Americans
 - peginterferons for, S47-S52
 - viral kinetics in, S29-S33
 - chronic
 - antiretroviral therapy in, hepatotoxicity of, evaluation for, 107-114
 - clinical development of, 149-166
 - cirrhosis in, clinical manifestations of, 149-166
 - diagnosis of, S3-S11
 - end-stage liver disease in, clinical manifestations of, 149-166
 - epidemiology of, 149-166
 - extrahepatic manifestations of, 149-166
 - and hepatocellular carcinoma, 149-166
 - in HIV-infected (AIDS) patients, 149-166
 - diagnosis of, 149-166
 - and hepatotoxicity of HIV-1 protease inhibitors, 183-193
 - and hepatotoxicity of non-nucleoside analog reverse transcriptase inhibitors, 173-181
 - histologic assessment of, 149-166
 - natural history of, 149-166
 - screening for, 149-166
 - treatment of, 107-114, 149-166, S47-S52
 - virology of, 149-166
 - in obese patients, viral kinetics in, S29-S33
 - pathogenesis of, 149-166
 - transmission of, 149-166
 - treatment of, 107-114, S3-S11
 - peginterferons for, S1-S2
 - pharmacokinetics of, S13-S18, S19-S22, S23-S28
 - and viral load, S13-S18
 - vaccine, 149-166
 - viral genomics in, S3-S11
 - viral kinetics in, S3-S11, S13-S18
 - obesity and, S29-S33
 - peginterferon pharmacodynamics and, S23-S28
 - race and, S29-S33
 - in special patient populations, S29-S33
- Hepatitis C virus (HCV)
 - antibodies to, S3-S11
 - antivirals specific for, 149-166
 - core antigen, S3-S11
 - dynamics, modeling of, S13-S18
 - and GB virus type C, comparison of, 137-148
 - genomics, S3-S11
 - genotype, S3-S11
 - and response to therapy, S29-S33, S35-S46
 - and viral kinetics, S29-S33
 - resistance to new inhibitors, S3-S11
 - RNA, quantification of, S3-S11
 - virology of, 149-166
- Hepatitis E, acute liver failure caused by, 239-250
- Hepatitis G virus. *See* GB virus type C
- Hepatoblast cell lines, 313-324, 349-361
- Hepatoblasts
 - fetal liver, isolation of, 349-361
 - phenotypic characteristics of, 349-361
 - rodent, 303-312, 313-324
- Hepatocarcinogenesis, hepatic progenitor cells and, 385-396
- Hepatocellular carcinoma (HCC)
 - in hepatitis B
 - immune response and, 21-37
 - and prognosis, 47-58
 - risk factors for, 89-100
 - surveillance for, 89-100, 125-136
 - in hepatitis C, 149-166
 - management of, 89-100
- Hepatocyte cell lines, Met murine, 313-324

- Hepatocytes
- apoptosis, in acute liver failure, 203-215
 - in bioartificial liver support devices, for acute liver failure, 283-294
 - bone marrow-derived, 363-371
 - therapeutic use of, 363-371
 - after bone marrow transplantation, 363-371
 - differentiation
 - from embryonic stem cells, 349-361
 - from hematopoietic stem cells, 349-361, 363-371
 - from multipotential adult progenitor cells, 313-324
 - from stem cells, 303-312, 313-324
 - necrosis, in acute liver failure, 203-215
 - regeneration, in rat liver, 325-335
- Hepatotoxicity
- of acetaminophen, 203-215, 217-226, 227-237
 - dose and, 227-237
 - definition of, 173-181
 - drug-related
 - diagnosis of, 107-114
 - in HIV-infected (AIDS) patients, 107-114
 - of HIV-1 protease inhibitors, 107-114, 183-193
 - of non-nucleoside analogue reverse transcriptase inhibitors, 107-114, 173-181
 - of nucleoside analogue reverse transcriptase inhibitors, 107-114, 167-171
- Highly active antiretroviral therapy (HAART), 115-123
- hepatotoxicity of, 173-181, 183-193
- HIV-1 protease inhibitors
- hepatotoxicity of, 107-114, 183-193
 - pharmacology of, 183-193
- Hong Kong, fulminant hepatic failure in, 239-250
- Human immunodeficiency virus (HIV)
- cellular reservoirs of, 115-123
 - and GB virus type C, interaction of, 137-148
 - hepatic effects of, 149-166
 - and hepatitis B coinfection
 - diagnosis of, 125-136
 - epidemiology of, 125-136
 - and hepatotoxicity of HIV-1 protease inhibitors, 183-193
 - and hepatotoxicity of non-nucleoside analog reverse transcriptase inhibitors, 173-181
 - natural history of, 125-136
 - treatment of, 125-136
 - and hepatitis C coinfection, 149-166
 - diagnosis of, 149-166
 - and hepatotoxicity of HIV-1 protease inhibitors, 183-193
 - and hepatotoxicity of non-nucleoside analog reverse transcriptase inhibitors, 173-181
 - histologic assessment of, 149-166
 - natural history of, 149-166
 - screening for, 149-166
 - treatment of, 107-114, 149-166, S47-S52
 - virology of, 149-166
 - immunologic control of, 115-123
 - infection
 - clinical features of, 149-166
 - epidemiology of, 149-166
 - natural history of, 115-123
 - HBV coinfection and, 125-136
 - pathogenesis of, 115-123, 149-166
 - survival with, GB virus type C and, 137-148
 - treatment of, 107-114, 115-123
 - hepatotoxicity of, 173-181
 - viral and cellular dynamics in, 115-123
 - life cycle of, 115-123
 - and liver, 107-114, 115-123
 - transmission of, 149-166
 - vaccine, 149-166
 - virology of, 107-114, 149-166
- Hypersensitivity reactions, with non-nucleoside analog reverse transcriptase inhibitors, 173-181
- Hyperventilation, for acute liver failure, 271-282
- Hypothermia, in management of fulminant hepatic failure, 251-258, 271-282
- Idiosyncratic drug reactions, acute liver failure caused by, 217-226
- Immune response
- in hepatitis B, 1-4, 21-37
 - to human immunodeficiency virus, 115-123
- Indinavir
- hepatotoxicity of, 183-193
 - pharmacology of, 183-193
- Indomethacin, for acute liver failure, 271-282
- Infections, and hepatic encephalopathy, 259-269
- Interferon- α
- adverse effects and side effects of, in HIV-infected (AIDS) patients, 149-166
 - for hepatitis B, 125-136
 - adverse effects and side effects of, 69-79
 - in children, 59-68
 - with decompensated cirrhosis, 89-100
 - duration of, 69-79
 - and famciclovir, combined, 81-88
 - in HBeAg-negative patients, 81-88
 - in HBeAg-positive patients, 69-79
 - prednisone priming with, 69-79
 - in HIV-infected (AIDS) patients, 125-136
 - and lamivudine, combined, 69-79, 81-88, 125-136
 - outcome with, 47-58
 - pegylated
 - for hepatitis C, 107-114, S1-S2
 - maintenance therapy with, S35-S46
 - nonresponse to, management of, S35-S46
 - pharmacokinetics of, S13-S18, S19-S22
 - race and, S47-S52
 - relapse after, management of, S35-S46
 - in special populations, S47-S52
 - pharmacokinetics of, S13-S18, S19-S22, S23-S28
 - and ribavirin, combined, for hepatitis C, 149-166
 - in alcohol abusers, S47-S52
 - clinical trial results of, S35-S46
 - in HIV-infected (AIDS) patients, 149-166, S47-S52
 - obesity and, S29-S33
 - pharmacokinetics of, S23-S28, S29-S33
 - race and, S29-S33, S47-S52
 - viral genomics and, S29-S33
 - structure of, S19-S22
- Interferon alfacon-1, S23-S28
- Interferons, long-acting, pharmacokinetics of, S23-S28

- Intracranial pressure
increased, in acute liver failure, 259-269, 271-282
monitoring, in acute liver failure, 271-282
- Isoniazid, acute liver failure caused by, 217-226
- Jeune syndrome, hepatic manifestations of, 195-200
- Lactate, cerebral concentrations of, in acute liver failure, 251-258, 259-269
- Lactic acidosis, with nucleoside reverse transcriptase inhibitor therapy, 167-171
- Lamivudine. *See also* Nucleoside analogue reverse transcriptase inhibitors
for hepatitis B, 81-88, 89-100
in children, 59-68
and cirrhosis, 89-100
outcome with, 47-58
and famciclovir, combined, 69-79, 81-88
in HBeAg-negative patients, 81-88
in HBeAg-positive patients, 69-79
in HIV-infected (AIDS) patients, 125-136
immune response and, 21-37
and interferon, combined, 69-79, 81-88, 125-136
prednisolone priming with, 69-79
prophylaxis after liver transplantation, 89-100
and transplantation, 89-100
viral resistance to, 5-20, 69-79, 81-88, 89-100, 107-114, 125-136
- Lipodystrophy syndrome, HIV-1 protease inhibitors and, 107-114
- Liver
adult, stem cells in, 337-348, 349-361
embryonic, bipotential cell lines from, 313-324
fetal
epithelial cells, hepatocyte potential of, 303-312
in humans, 373-383
stem cells in, 337-348
inflammatory mass lesion of, 101-106
injury, response to, cells involved in, 363-371. *See also* Liver repopulation
regeneration
in acute liver failure, 203-215
in humans, 385-396
submassive necrosis, liver regeneration after, 385-396
- Liver disease
pediatric, progenitor cells in, 385-396
progenitor cells in, 385-396
- Liver failure
acute, 203-215. *See also* Liver failure, fulminant
in children, 217-226
clinical features of, 217-226
clinical pathophysiology of, 259-269, 271-282
CNS complications of, pathogenesis of, 251-258, 259-269
epidemiology of, 217-226
etiologies of, 217-226, 227-237, 239-250
hepatocellular regeneration in, 203-215
hepatocyte injury in, mechanisms of, 203-215
in Hong Kong and Far East, 239-250
intensive care for, 217-226
intracranial hypertension in, 259-269, 271-282
liver support devices in, 283-294
liver transplantation for, 217-226, 227-237, 239-250
management of, pathophysiologic basis of, 271-282
medical treatment of, 239-250
molecular neurobiology of, 251-258
nonacetaminophen-induced, 203-215, 217-226, 227-237
outcomes with, 203-215, 217-226
prognosis for, 203-215, 217-226
treatment of, 217-226
hypothermia in, 251-258, 271-282
neuropharmacology of, 251-258
in United Kingdom, 227-237
in United States, 217-226
fulminant, 201-202, 217-226. *See also* Liver failure, acute
in L-asparaginase-induced liver disease, 295-299
- Liver repopulation, 337-348, 349-361
bone marrow stem cells in, 363-371
in rat, 325-335
- Liver support devices, in acute liver failure, 283-294
- Liver transplantation
for acute liver failure, 217-226, 227-237, 239-250, 271-282
in L-asparaginase-induced liver disease, 295-299
in Far East, 239-250
in hepatitis B, 239-250
with decompensated liver disease, 89-100
in HIV-infected (AIDS) patients, 125-136
in HIV-infected (AIDS) patients, 107-114, 125-136
increased intracranial pressure during, prevention of, 271-282
in Jeune syndrome, 195-200
and lamivudine for hepatitis B, 89-100
living-donor, for fulminant hepatic failure, 239-250
patterns of use of, in United Kingdom, 227-237
- Lopinavir/ritonavir
hepatotoxicity of, 183-193
pharmacology of, 183-193
- Mitochondria, in toxic liver injury, with nucleoside reverse transcriptase inhibitor therapy, 107-114, 167-171
- Multiorgan failure, in liver failure, 203-215
- Necrosis, hepatocyte
in acute liver failure, 203-215
and hepatic encephalopathy, 259-269
- Nelfinavir
hepatotoxicity of, 183-193
pharmacology of, 183-193
- Nevirapine, hepatotoxicity of, 107-114, 173-181
- Nonalcoholic fatty liver disease, progenitor cell activation in, 385-396
- Non-nucleoside analog reverse transcriptase inhibitors, hepatotoxicity of, 107-114, 173-181
- Nucleoside analogue reverse transcriptase inhibitors. *See also* Lamivudine
for hepatitis B, 69-79, 107-114
combination of, 69-79, 125-136
viral resistance to, 5-20, 69-79, 81-88, 89-100
hepatotoxicity of, 107-114, 167-171
- L-Nucleosides, for hepatitis B, 81-88

- Osmoregulation, and hepatic encephalopathy, 251-258, 259-269
- Oval cells
- after bone marrow transplantation, 363-371
 - cell lines, 313-324, 349-361
 - hepatic, 337-348, 349-361, 363-371, 385-396
 - hematopoietic markers on, 363-371
 - rodent, 303-312, 313-324, 325-335
- Pancreas, inflammatory mass lesion of, 101-106
- Pancreatic cells
- hepatocyte potential of, 303-312
 - rat, with hepatocyte potential, 325-335
- PEGASYS. *See* Peginterferon alfa-2a (PEGASYS)
- Peginterferon alfa-2a (PEGASYS)
- for hepatitis C, sustained virological response to, S29-S33, S35-S46
 - pharmacodynamics of, and viral kinetics, S23-S28
 - pharmacokinetics of, S19-S22, S23-S28
 - structure of, S19-S22
- Peginterferon alfa-2b (PEG-Intron)
- for hepatitis C, sustained virological response to, S29-S33, S35-S46
 - pharmacodynamics of, and viral kinetics, S23-S28
 - pharmacokinetics of, S19-S22, S23-S28
 - structure of, S19-S22
- Peginterferons
- for hepatitis C, S1-S2
 - in African Americans, S47-S52
 - in alcohol abusers, S47-S52
 - in HIV-infected (AIDS) patients, S47-S52
 - maintenance therapy with, S35-S46
 - nonresponse to, management of, S35-S46
 - pharmacokinetics of, S13-S18, S19-S22, S23-S28
 - relapse after, management of, S35-S46
 - in special populations, S47-S52
 - sustained virological response to, S29-S33, S35-S46
 - pharmacokinetics of, S13-S18, S19-S22, S23-S28
 - structure of, S19-S22
- PEG-Intron. *See* Peginterferon alfa-2b (PEG-Intron)
- Plasma, osmolarity, in acute liver failure, 259-269
- Portal hypertension, in Jeune syndrome, 195-200
- Prednisolone priming, with lamivudine therapy, 69-79
- Prednisone priming, with interferon therapy, 69-79
- Progenitor cells. *See also* Oval cells
- adult, multipotential, 363-371
 - hepatocyte differentiation from, 313-324
 - adult liver
 - bipotential, 349-361
 - localization of, 349-361
 - unipotential, 349-361
 - fetal liver
 - clonal expansion of, 349-361
 - isolation of, 349-361
 - hepatic
 - activation of, 385-396
 - in biliary disease, 385-396
 - control of, 385-396
 - differentiation of, 385-396
 - control of, 385-396
 - in diseased human liver, 385-396
 - and hepatocarcinogenesis, 385-396
 - human, phenotype of, 385-396
 - in pediatric liver disease, 385-396
 - small hepatocyte-like, 349-361
- Propofol, for acute liver failure, 271-282
- Reverse transcription, in hepatitis B viral replication, 5-20
- Ribavirin
- adverse effects and side effects of, 149-166
 - anemia caused by, treatment of, 107-114
 - and didanosine, interactions of, 107-114
 - and pegylated interferon, combined, for hepatitis C, 149-166
 - in African Americans, S29-S33, S47-S52
 - in alcohol abusers, S47-S52
 - clinical trial results of, S35-S46
 - in HIV-infected (AIDS) patients, 149-166, S47-S52
 - obesity and, S29-S33
 - pharmacokinetics of, S23-S28, S29-S33
 - and stavudine, interactions of, 107-114
- Ritonavir
- hepatotoxicity of, 183-193
 - pharmacology of, 183-193
- Saquinavir
- hepatotoxicity of, 183-193
 - pharmacology of, 183-193
- Seizures, in hepatic encephalopathy, 259-269
- Self-poisoning
- with acetaminophen, 227-237
 - with multidrug cocktails, 227-237
- Shock, acute liver failure caused by, 217-226
- Side population cells, 337-348
- Stavudine. *See also* Nucleoside analogue reverse transcriptase inhibitors
- and ribavirin, interactions of, 107-114
- Steatohepatitis, nonalcoholic, 107-114
- Steatosis, in L-asparaginase-induced liver disease, 295-299
- Stem cells. *See also* Progenitor cells
- adult, plasticity of, 349-361
 - bone marrow, 303-312, 325-335
 - conversion to hepatocytes, mechanism of, 363-371
 - in liver regeneration, 363-371
 - transdifferentiation of, 349-361
 - and cell fusion, 349-361, 363-371, 373-383
 - embryonic, 303-312, 313-324, 325-335
 - differentiation of, into hepatocytes, 349-361
 - hematopoietic
 - and hepatic stem cells, relationship between, 373-383
 - hepatocyte differentiation from, 349-361
 - as hepatocyte precursors, 363-371
 - hepatic, 301
 - in adult, 337-348, 349-361, 373-383
 - biomedical applications of, 373-383
 - differentiation of, 303-312
 - molecular control of, 373-383
 - fetal, 337-348, 349-361
 - H-CFU-C, 337-348
 - and hematopoietic stem cells, relationship between, 373-383

- human, isolation and characterization of, 373-383
- isolation and characterization in vitro, 313-324
- isolation and characterization of, 313-324, 373-383
- and liver repopulation, 325-335, 337-348, 349-361
- postnatal, 373-383
- recent experimental studies of, 303-312
- therapeutic applications of, 373-383
- human liver-derived, 373-383
- markers, 303-312, 313-324, 325-335, 337-348, 349-361, 373-383
- plasticity of, 349-361, 363-371
- rat-derived, differentiation capacity of, characterization of, 325-335
- tissue-specific, 349-361
- transdifferentiation of, 349-361, 373-383
- Synergistic toxins, and hepatic encephalopathy, 259-269
- Systemic inflammatory response, and increased intracranial pressure in acute liver failure, 271-282
- Telbivudine, for hepatitis B, 125-136
- Tenofovir. *See also* Nucleoside analogue reverse transcriptase inhibitors
 - for chronic hepatitis B, 107-114
 - in HIV-infected (AIDS) patients, 125-136
 - for hepatitis B, 89-100
- Thiopental sodium, for acute liver failure, 271-282
- Troglitazone, acute liver failure caused by, 217-226
- United Kingdom, acute hepatic failure in, 227-237
- United States, acute hepatic failure in, 217-226
- Xanthogranulomatous cholecystitis, 101-106
- Zalcitabine. *See* Nucleoside analogue reverse transcriptase inhibitors
- Zidovudine. *See* Nucleoside analogue reverse transcriptase inhibitors



